The Enduring Legacy of SARS-CoV-2

[AribertDeckers]

16.8.2025
The Enduring Legacy of SARS-CoV-2


Helping to push these texts I archive them here.

Graphics, pictures, tables, embedded URLs you will find only in the originals. So, do read the originals!


https://davidlingenfelter.substack.com/p/the-enduring-legacy-of-sars-cov-2

[*quote*]
----------------------------------
The Enduring Legacy of SARS-CoV-2: A Global Analysis of Infection-Induced Chronic Disease and Altered Pathogen Susceptibility

SARS-CoV-2 drives chronic illness and immune dysfunction, increasing risks from reinfection, latent viruses, and co-infections—making the world sicker long-term.
David Lingenfelter, PhD
Aug 15, 2025
Executive Summary

The ongoing global circulation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) presents a formidable and evolving challenge to public health that extends far beyond the acute phase of infection. This report critically evaluates the hypothesis that continued population-wide infection with SARS-CoV-2 will result in a sicker global population, mediated through two primary mechanisms: the induction of a widespread, multi-system chronic disease, and complex pathogen-pathogen interactions that alter host immunity. A comprehensive synthesis of current clinical and immunological research affirms this hypothesis. The evidence demonstrates that a substantial percentage of individuals infected with SARS-CoV-2 develop a debilitating post-acute syndrome known as Long COVID or Post-Acute Sequelae of COVID-19 (PASC). This condition, characterized by a vast constellation of symptoms and the potential for long-term disability, is driven by a confluence of pathophysiological processes including persistent immune dysregulation, viral reservoirs, microvascular injury, and autoimmunity. Furthermore, each subsequent infection appears to add to a cumulative burden of risk for these chronic sequelae. Concurrently, SARS-CoV-2 infection inflicts lasting damage on the host immune system, creating a state of dysregulation that impairs its ability to control other pathogens. This is evidenced by a well-documented increase in the reactivation of latent viruses, such as Epstein-Barr virus and Varicella-Zoster virus, and a markedly elevated risk of severe outcomes from secondary bacterial co-infections. While the impact on susceptibility to other acute respiratory viruses is more complex, the overall picture is one of a global population with compromised baseline health and diminished immunological resilience. This report concludes that the enduring legacy of the COVID-19 pandemic will be defined not only by its acute mortality but by a significant, long-term increase in chronic illness and altered susceptibility to a range of other infectious threats, thereby validating the assertion that ongoing SARS-CoV-2 infection is, indeed, making the world sicker.
Part I: The Burden of Infection-Induced Chronic Disease: Post-Acute Sequelae of SARS-CoV-2 (PASC)

The first pillar of the hypothesis under examination posits that SARS-CoV-2 infection is a direct and significant driver of chronic disease on a global scale. The emergence of a complex, multi-system, and often disabling condition following acute COVID-19, now widely recognized as Long COVID or PASC, provides substantial evidence to support this claim. This section will establish the scale of this public health crisis by defining the syndrome, quantifying its prevalence and persistence, and exploring the profound impact it has on individuals and society. The data collectively demonstrate that PASC is not a rare or transient phenomenon but a common and enduring consequence of SARS-CoV-2 infection, fundamentally altering the health trajectory of millions worldwide.
Section 1: The Scale and Scope of Long COVID

To comprehend the long-term impact of SARS-CoV-2, it is first necessary to quantify the problem of post-acute sequelae. This requires a clear understanding of the clinical definition of Long COVID, the breadth of its symptomatology, its global prevalence, and its chronicity. The epidemiological data presented in this section frame Long COVID not as a footnote to the acute pandemic but as a central and ongoing mass-casualty event, characterized by its high incidence and potential for inducing long-term disability.
1.1 Defining the Syndrome: Clinical Definitions and Symptom Constellations

The formal recognition and definition of Long COVID by major public health organizations has been a critical step in characterizing the post-pandemic landscape. The U.S. Centers for Disease Control and Prevention (CDC) defines Long COVID as a chronic condition that occurs after SARS-CoV-2 infection and is present for at least three months.1 This definition emphasizes the dynamic nature of the illness, noting that symptoms can emerge, persist, resolve, and reemerge over extended periods.1 The World Health Organization (WHO) offers a similar definition, specifying the continuation or development of new symptoms three months after the initial infection, with these symptoms lasting for at least two months with no other explanation.2 While these definitions provide a crucial framework, the research landscape is complicated by varying criteria; for instance, the National Institute for Health and Care Excellence (NICE) in England defines Long COVID as signs and symptoms that continue or develop after four weeks post-infection.3 This heterogeneity, while posing challenges for direct comparison across studies, collectively underscores the clinical reality of a persistent and significant post-viral state.

The clinical presentation of Long COVID is extraordinarily diverse, affecting nearly every organ system and encompassing more than 200 identified symptoms.5 This multi-systemic impact is a hallmark of the condition. The most commonly reported symptoms include a profound and debilitating fatigue that interferes with daily life, post-exertional malaise (PEM), where physical or mental effort leads to a severe worsening of symptoms, and cognitive dysfunction, often described as "brain fog".3

A systematic categorization of these symptoms reveals the widespread nature of the pathology:

    General and Systemic: Pervasive fatigue, PEM, and fever are frequently reported, indicating a state of systemic illness.4

    Neurological and Neuropsychiatric: This is one of the most heavily affected domains, with symptoms including brain fog, memory problems, headaches, sleep disturbances, dizziness upon standing (lightheadedness), pins-and-needles sensations, and changes in smell or taste. Furthermore, new-onset depression and anxiety are common neuropsychiatric manifestations.5

    Cardiopulmonary: Respiratory and heart symptoms are prevalent, including difficulty breathing or shortness of breath, persistent cough, chest pain, and a fast-beating or pounding heart, also known as palpitations.5

    Other Organ Systems: The impact extends to the gastrointestinal system (diarrhea, stomach pain, constipation), the musculoskeletal system (joint or muscle pain), and the dermatological system (rashes).5 Changes in menstrual cycles are also reported.5

Beyond this extensive list of symptoms, a critical aspect of PASC is its capacity to trigger or unmask new, diagnosable chronic health conditions. Individuals who have had COVID-19 are at a higher risk of developing new or worsened conditions such as diabetes, heart disease, blood clots (thromboembolic disease), and various neurological disorders.5 This evidence firmly establishes that SARS-CoV-2 infection can act as a catalyst for lifelong chronic illness, shifting an individual's health status from healthy to chronically ill, often in a single event.
1.2 Global Prevalence and Persistence: A Quantitative Analysis

The scale of the Long COVID crisis is underscored by robust epidemiological data. A comprehensive systematic review and meta-analysis published between 2021 and 2024, which included 429 studies, estimated a pooled global prevalence of Long COVID at a staggering 36% among individuals with a confirmed COVID-19 diagnosis.7 This figure refutes any notion that PASC is a rare outcome, instead positioning it as a common and predictable consequence of SARS-CoV-2 infection. The burden is even more concentrated in certain high-exposure populations; a separate meta-analysis focusing on healthcare workers (HCWs) found a pooled prevalence of 40%, highlighting the occupational risk associated with repeated viral exposure.4

Perhaps the most concerning finding from recent large-scale analyses is the chronicity of the condition. Early in the pandemic, it was hoped that these lingering symptoms represented a prolonged but ultimately self-resolving recovery period. However, evidence now strongly contradicts this optimistic view. The global meta-analysis found no statistically distinguishable difference in Long COVID prevalence when comparing follow-up periods of less than one year (35%, 95% CI 31%-39%) with longer follow-up periods of one to two years (47%, 95% CI 37%-57%).7 The overlapping confidence intervals indicate that, at a population level, the burden of Long COVID does not significantly diminish even as time from the initial infection extends into years. This critical finding shifts the conceptual framework of PASC from that of a slow recovery to that of a persistent chronic illness for a substantial subset of those infected. This conclusion is further supported by longitudinal cohort studies, which have tracked patients over time. One such study found that up to 18% of unvaccinated individuals still had post-COVID-19 conditions two years after their initial infection.12 Another prospective longitudinal study of vaccinated adults who experienced mild infection found a persistent Long COVID symptom prevalence of 21.5% at the two-year mark.13 The convergence of evidence from meta-analyses and long-term cohort studies paints a clear picture: for millions of people, Long COVID is not a transient state but a chronic reality.

Table 1: Global Prevalence and Symptom Subtypes of Long COVID

Data synthesized from a meta-analysis of 429 studies published 2021-2024.7
1.3 Long COVID as a Disabling Condition: Parallels with ME/CFS

The clinical and societal impact of Long COVID is crystallized by its recognition as a potentially disabling condition. The CDC explicitly states that the symptoms and conditions associated with Long COVID can result in disability, requiring comprehensive care and significantly altering an individual's quality of life.1 The constellation of symptoms, particularly the triad of post-exertional malaise, severe fatigue, and cognitive impairment, directly interferes with the ability to perform activities of daily living, maintain employment, and participate in society.5 The economic consequences are severe; a longitudinal cohort study found that individuals with current Long COVID had significantly higher odds of experiencing moderate to high financial toxicity and work loss compared to those who recovered fully.15 This demonstrates that the high prevalence of Long COVID is translating into a mass disabling event with profound implications for workforce participation and economic stability.

Further insight into the nature of Long COVID can be gained by examining its striking clinical overlap with other post-infectious chronic illnesses, most notably Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).1 ME/CFS is a complex, debilitating chronic disease that often follows an infectious trigger and is characterized by many of the same core symptoms as Long COVID, including profound fatigue, PEM, cognitive dysfunction, and autonomic nervous system dysregulation.5 A systematic review comparing post-COVID conditions in children with other post-viral syndromes, such as after Epstein-Barr Virus (EBV) infection, confirms a significant overlap in symptom profiles, particularly post-viral fatigue.16 This comparison is not merely descriptive; it situates Long COVID within a known, albeit historically neglected, class of post-viral diseases. This connection suggests the potential for shared underlying pathophysiological mechanisms, such as persistent immune dysregulation or latent viral reactivation, and provides a valuable, if sobering, historical context for understanding the potential long-term trajectory and societal burden of this new mass cohort of chronically ill individuals. The challenges faced by the ME/CFS community—including difficulties in obtaining a diagnosis, being believed by healthcare providers, and managing debilitating symptoms—are now being replicated on a massive scale within the Long COVID population.5
Section 2: The Pathophysiological Underpinnings of Long COVID

Understanding why SARS-CoV-2 infection leads to chronic illness in such a large proportion of individuals requires a deep investigation into the underlying biological mechanisms. The pathophysiology of Long COVID is not attributable to a single cause but rather a complex and interconnected web of pathological processes. Research has converged on several key hypotheses that are not mutually exclusive and likely interact to create a self-perpetuating cycle of illness. These include a profound and persistent dysregulation of the immune system, the establishment of viral or antigenic reservoirs, widespread microvascular injury driven by abnormal blood clotting, and the de novo induction of autoimmune processes.
2.1 Immune Dysregulation and Chronic Inflammation: The Central Hypothesis

A central and unifying theory for the diverse symptoms of Long COVID is that they are driven by a prolonged, dysregulated, and non-resolving immune-inflammatory response.17 In a normal immune response to an acute infection, inflammation is a necessary and temporary process that is tightly regulated and subsides once the pathogen is cleared. In Long COVID, this process becomes decoupled from the initial infection, leading to a state of chronic hyperinflammation. Studies have shown that long after the acute phase, patients with PASC have persistently elevated levels of key pro-inflammatory cytokines, including interleukin-1β (IL−1β), interleukin-6 (IL−6), and tumor necrosis factor-α (TNF−α).17 This systemic inflammation can account for general symptoms like fatigue and fever, while localized inflammation in the central nervous system—neuroinflammation—is a leading explanation for the severe neurological symptoms of brain fog, memory loss, and mood disturbances.6

This chronic inflammatory state is not merely a chemical imbalance but is rooted in profound and lasting dysfunction at the cellular level of the immune system. Comprehensive immunophenotyping studies have revealed a deeply altered immune landscape in individuals with Long COVID. This includes an enrichment of immature, pro-inflammatory monocytes that exhibit sustained activation of the inflammasome, a key engine of inflammation.18 The adaptive immune system is also severely affected, with evidence of senescence (premature aging and dysfunction) in CD8 T-cells, which are critical for killing virally infected cells.18 Furthermore, studies have identified a fundamental breakdown in the coordination between different arms of the immune system. In many Long COVID patients, unusually high levels of antibodies against SARS-CoV-2 persist but do not synchronize with the activity of T-cells as they normally would, pointing to a disorganized and inefficient long-term immune response.19

The origins of this immune dysfunction may lie in the earliest stages of the immune response. Research indicates that severe COVID-19 can induce long-lasting epigenetic changes—modifications to how genes are expressed without changing the DNA sequence itself—in the hematopoietic stem cells that give rise to all immune cells.20 These changes effectively "reprogram" the immune system towards a hyper-inflammatory state. Monocytes derived from these altered stem cells are primed to overproduce inflammatory cytokines in response to stimulation, a state that has been observed for up to a year after the initial infection.20 This finding provides a powerful mechanistic link between a transient viral infection and a persistent, chronic inflammatory disease.
2.2 Viral Persistence and Antigenic Reservoirs

The observation of a chronically activated immune system strongly suggests that in many cases of Long COVID, the immune system is responding to a persistent trigger. A leading hypothesis is that SARS-CoV-2, or its components, are not fully cleared from the body after the acute infection resolves.17 Instead, the virus may establish persistent reservoirs in various tissues, such as the gut, nervous tissue, or other organs. This is not a chronic active infection in the traditional sense but rather a low-level, smoldering presence of intact virus or viral fragments (particularly the immunogenic spike protein) that continually stimulates the immune system.19

This theory of viral persistence provides a direct causal link between the initial infection and the long-term symptoms of PASC. The ongoing presence of viral antigens would logically lead to the chronic T-cell activation, elevated cytokine levels, and uncoordinated antibody responses observed in patients.19 This persistent immune stimulation, fueled by viral reservoirs, can lead to ongoing, localized tissue damage and inflammation, explaining the multi-organ nature of the disease.22 While direct proof of such reservoirs in living patients is technically challenging to obtain, the immunological evidence for a sustained response to a persistent antigen is compelling and remains a primary focus of ongoing research.
2.3 Microvascular Injury and Fibrin Amyloid Microclots

Beyond direct immune-mediated damage, a growing body of evidence points to the vascular system, specifically the microvasculature, as a key site of pathology in Long COVID. SARS-CoV-2 infection is known to induce a hypercoagulable or prothrombotic state, and this appears to persist in PASC.23 A specific and highly compelling mechanism involves the formation of anomalous fibrin amyloid microclots.23 These are not typical blood clots; they are microscopic, resistant to the body's natural fibrinolytic (clot-dissolving) machinery, and have an amyloid-like structure.24

The formation of these pathological microclots appears to be directly induced by the SARS-CoV-2 spike protein, which can interact with fibrinogen in the blood to create these dense, insoluble aggregates.23 These microclots have been identified in the plasma of Long COVID patients and serve a dual pathological role. First, they are large enough to block the body's smallest blood vessels—the capillaries—thereby impairing the exchange of oxygen between the blood and the tissues.23 This widespread tissue hypoxia provides a powerful and unifying explanation for many of the cardinal symptoms of Long COVID, including profound fatigue, muscle pain (myalgia), and cognitive dysfunction, by linking them to a fundamental failure of cellular energy supply. Second, proteomic analysis of these microclots reveals that they are not inert but act as sponges for numerous pro-inflammatory molecules, including various cytokines and clotting factors.24 By trapping these molecules, the microclots create localized pockets of high inflammation and further promote a prothrombotic state, thus perpetuating the vicious cycle of inflammation and microvascular occlusion that characterizes the disease.
2.4 The Emergence of Autoimmunity and Mast Cell Activation Syndrome (MCAS)

The profound and prolonged disruption of the immune system by SARS-CoV-2 can lead to a breakdown in self-tolerance, the process by which the immune system distinguishes the body's own cells from foreign invaders. This can result in the development of new-onset autoimmune diseases, where the immune system mistakenly attacks healthy tissues.5 Several mechanisms are proposed to explain this phenomenon. One is "molecular mimicry," where antibodies or T-cells created to fight SARS-CoV-2 cross-react with human proteins that bear a structural resemblance to viral proteins.25 Another is the general, massive inflammatory response during acute COVID-19, which can cause "bystander activation" of self-reactive immune cells. Large-scale studies have quantified this risk, finding that a prior COVID-19 infection is associated with a 42% increased chance of being diagnosed with an autoimmune disease, including conditions like rheumatoid arthritis, lupus, and inflammatory bowel disease, in the months following infection.25

A related phenomenon that appears to be highly prevalent in Long COVID is Mast Cell Activation Syndrome (MCAS).27 Mast cells are immune cells located in tissues throughout the body that, when activated, release a potent cocktail of inflammatory mediators like histamine. In Long COVID, the persistent inflammatory environment can lead to the chronic, abnormal activation of these cells.27 The clinical consequences are significant, as the symptoms of MCAS—which can include flushing, rapid heart rate (tachycardia), gastrointestinal distress, dizziness, and brain fog—are described as "virtually identical" to many of the symptoms reported by patients with Long COVID.27 This suggests that MCAS is not just a coincidental finding but may be a key driver of the clinical syndrome in a large subset of patients. This finding is particularly important as it points to potential therapeutic strategies, such as mast cell stabilizers and antihistamines, that could alleviate a significant symptom burden for these individuals.
Section 3: The Cumulative Risk from Reinfection and the Modulating Role of Vaccination

The individual risk of developing Long COVID is not static but is influenced by subsequent encounters with the virus and by prior vaccination status. Understanding these modifying factors is crucial for assessing the long-term public health impact of the continued circulation of SARS-CoV-2. The evidence indicates that while vaccination provides a significant degree of protection, each reinfection represents a renewed and cumulative risk, challenging the notion that repeated infections lead to benign illness.
3.1 The Cumulative Burden of Repeated SARS-CoV-2 Infections

The question of how reinfection impacts the risk of Long COVID is complex, with initial studies yielding seemingly paradoxical results. Some analyses have suggested that the risk of developing new-onset Long COVID after a second infection is lower than the risk after a first infection.28 This could be due to several factors, including partial immunity conferred by the first infection or a selection bias where individuals most susceptible to developing PASC did so after their initial exposure.

However, a more comprehensive and concerning picture emerges from large-scale longitudinal studies that track the cumulative health burden over multiple infections. These studies reveal that the overall risk of adverse health outcomes, including Long COVID and damage to multiple organ systems, increases in a dose-dependent manner with each subsequent SARS-CoV-2 infection.31 The data show that the adverse health effects from two infections are worse than from one, and the effects from three infections are worse than from two.32 This cumulative model suggests that each infection acts as an additional inflammatory insult, progressively increasing the likelihood of long-term organ damage and the development of chronic sequelae across cardiac, pulmonary, and neurological systems.31 This perspective reframes each reinfection not as a benign "booster" but as another turn in a game of "Russian roulette" with one's long-term health.32 The clinical relevance of this is highlighted by a study of a Long COVID patient cohort, which found that nearly 85% of individuals with the condition had a history of multiple SARS-CoV-2 infections over a four-year period.33 This strong association underscores the idea that for many, Long COVID is the result of an accumulated burden of viral encounters.
3.2 The Protective Effect of Vaccination

In the face of the cumulative risk posed by reinfection, vaccination stands out as the single most effective tool for mitigating the long-term consequences of SARS-CoV-2. Being unvaccinated is identified as one of the strongest risk factors for developing Long COVID.7 Conversely, a robust body of evidence demonstrates that vaccination, whether administered before or after an initial infection, significantly reduces the risk of developing PASC.31 Studies have estimated this risk reduction to be between 15% and 41%.31

The benefits of vaccination extend beyond simply reducing the incidence of Long COVID. For individuals who do develop breakthrough infections and subsequent PASC, prior vaccination is associated with measurably better health outcomes. Vaccinated individuals with Long COVID report better physical and mental health scores on standardized quality-of-life measures and have 29% lower odds of work impairment compared to their unvaccinated counterparts.15 Furthermore, there is evidence that vaccination may even have a therapeutic effect for some individuals already suffering from Long COVID. A survey of over 800 people with the condition found that a majority (57.9%) reported an improvement in their symptoms following their first COVID-19 vaccination, particularly with mRNA vaccines, although for many the improvement was temporary.36 While vaccination is not a panacea and does not eliminate the risk of PASC entirely, it is a critical public health intervention that demonstrably lessens the overall burden of infection-induced chronic disease at both the individual and population levels.
Part II: The Compounding Effects of Pathogen-Pathogen Interaction

The second major component of the central hypothesis is that widespread SARS-CoV-2 infection makes the world sicker not only through the direct induction of chronic disease but also by altering the host's ability to respond to other pathogens. This creates a compounding health crisis where the impact of COVID-19 reverberates through the broader landscape of infectious diseases. This section will explore this dimension by first establishing the biological basis for these interactions—the long-term damage SARS-CoV-2 inflicts upon the human immune system—and then examining the clinical evidence for altered susceptibility to other viral and bacterial threats.
Section 4: SARS-CoV-2 and the Dysregulation of the Host Immune Landscape

The foundation for understanding how SARS-CoV-2 infection can alter susceptibility to other pathogens lies in its profound and lasting impact on the architecture and function of the human immune system. The virus does not merely trigger a transient response that returns to baseline; instead, it can induce a state of chronic dysregulation, effectively recalibrating the host's immune posture towards one of dysfunction. This altered immune landscape is the common mechanistic link between the symptoms of Long COVID and the broader phenomenon of pathogen-pathogen interaction.
4.1 Long-Term Alterations to Innate and Adaptive Immunity

The damage inflicted by SARS-CoV-2 spans both the innate and adaptive arms of the immune system. Studies have documented that the virus can affect and damage, at least temporarily, all major cell types of the immune system, including T-cells, B-cells, and monocytes.37 Importantly, these are not just short-term effects limited to the acute phase of illness; considerable long-term changes to the immune system have been documented even in individuals who experienced only mild initial disease.38

One of the key long-term consequences is a form of premature immune aging and exhaustion. The broad and intense activation of immune cells during a COVID-19 infection leads to increased cellular turnover, which can exhaust the proliferative capacity of these cells.37 This is particularly detrimental to the pool of "naive" T-cells, which are essential for recognizing and mounting a response to new, previously unencountered pathogens. The depletion of this naive T-cell repertoire effectively reduces the immune system's adaptability. Concurrently, the T-cells that are repeatedly stimulated can enter a state of "exhaustion," a dysfunctional state where they lose their ability to effectively clear pathogens. This has been observed particularly in CD8 T-cells, which are critical for eliminating virally infected cells.18 As detailed in Part I, this cellular dysfunction occurs against a backdrop of persistent, low-grade inflammation, characterized by the continued presence of pro-inflammatory monocytes and activated CD8+ T-cells long after the virus should have been cleared.17
4.2 Evidence for a SARS-CoV-2-Induced Immunodeficiency-like State

The cumulative effect of these long-term alterations—cellular damage, premature aging, exhaustion, and chronic inflammation—is a state of profound immune dysregulation where the immune system simply does not function properly.37 This state is characterized by a loss of coordination, where different components of the immune response fail to work in concert. For example, the sustained high levels of antibodies that fail to synchronize with T-cell activity are a hallmark of this disorganized response.19 This dysfunctional baseline leaves the host more vulnerable to subsequent pathogenic threats.37

This condition, while not equivalent to the profound T-cell depletion seen in advanced HIV/AIDS, shares certain features with immunodeficiency syndromes. It represents an acquired state of impaired immune function that compromises the body's ability to control latent infections and to mount an effective defense against new ones.41 The fact that each reinfection with SARS-CoV-2 can further damage the immune system creates the potential for a downward spiral of progressively weakening defenses with repeated exposures.37 This systemic "shock" to the immune system, which fundamentally recalibrates it toward a pro-inflammatory and exhausted state, is the unifying mechanism that explains both the intrinsic symptoms of Long COVID and the extrinsic vulnerability to other pathogens. The world becomes sicker not only from the direct consequences of PASC but from a population-level degradation of collective immune resilience.
Section 5: Reactivation of Latent Viruses and Onset of Opportunistic Infections

One of the most direct and clinically evident consequences of the immune dysregulation induced by SARS-CoV-2 is the host's impaired ability to control pathogens that are already present within the body in a dormant or latent state. A healthy immune system expends considerable resources on surveillance to keep these latent pathogens in check. When this surveillance is compromised by COVID-19, these dormant viruses can reactivate, leading to new or recurrent disease and contributing significantly to the post-acute symptom burden.
5.1 The Link Between SARS-CoV-2, Epstein-Barr Virus (EBV), and Varicella-Zoster Virus (VZV)

A primary function of a robust T-cell-mediated immune response is to maintain lifelong latency of common herpesviruses, such as Epstein-Barr virus (the cause of mononucleosis) and Varicella-Zoster virus (the cause of chickenpox and shingles).44 The T-cell depletion, exhaustion, and general dysfunction that are now well-documented consequences of SARS-CoV-2 infection directly compromise this critical control mechanism, creating a window of opportunity for these latent viruses to reactivate and replicate.44

The clinical consequences of this reactivation are significant and may be central to the Long COVID phenomenon itself. Reactivation of EBV is now being investigated as a major contributing factor to the symptoms of Long COVID.46 The symptom profile of chronic active EBV infection or EBV-associated ME/CFS—debilitating fatigue, cognitive issues, muscle pain—shows a remarkable overlap with the cardinal symptoms of Long COVID. A recent study provided quantitative evidence for this link, finding that 66.7% of subjects with Long COVID tested positive for EBV reactivation, suggesting a strong association.44 This finding raises the possibility that a substantial portion of what is clinically diagnosed as "Long COVID" may in fact be post-COVID reactivated EBV disease, a "disease within a disease" that has profound implications for both diagnosis and treatment.

A similar dynamic is observed with VZV. Reactivation of VZV from nerve ganglia causes herpes zoster, or shingles, a painful vesicular rash. A large study of unvaccinated individuals found that those who had a prior COVID-19 infection were 15% more likely to develop shingles than those who had not been infected. For individuals who had been hospitalized for COVID-19, the risk was 20% higher.45 This provides a clear, quantifiable clinical outcome directly resulting from the immune dysregulation induced by SARS-CoV-2.
5.2 Heightened Risk in Immunocompromised Populations

For individuals who already have a compromised immune system due to conditions like HIV, primary immunodeficiency (PI), or immunosuppressive treatments, SARS-CoV-2 infection represents a compounded threat.42 Their pre-existing immune weakness makes it more difficult to control and clear the initial SARS-CoV-2 infection, placing them at higher risk for severe acute disease.42 Furthermore, the additional immune damage inflicted by COVID-19 can push their already fragile systems into a state of profound vulnerability, increasing their risk for opportunistic infections (OIs).50

OIs are infections caused by pathogens that do not typically cause disease in individuals with a healthy immune system but can be severe or fatal in an immunocompromised host.50 The state of immune suppression observed during severe COVID-19, which is often exacerbated by necessary medical treatments like high-dose corticosteroids, creates a permissive environment for such infections. Clinical reports have documented a range of OIs in COVID-19 patients, including invasive fungal infections (e.g., Aspergillus, Candida, mucormycosis), reactivation of other viruses (e.g., Cytomegalovirus [CMV], Herpes simplex virus), and various parasitic and bacterial infections.51 This highlights how SARS-CoV-2 can act as a gateway pathogen, breaking down the body's defenses and allowing a host of other infectious agents to cause disease.
Section 6: Altered Susceptibility to Subsequent Viral and Bacterial Infections

The final dimension of pathogen-pathogen interaction concerns how a prior SARS-CoV-2 infection alters the risk and clinical course of encounters with new, external pathogens. The evidence here is complex and reveals that the immune dysregulation caused by COVID-19 is not a simple, uniform suppression. Instead, it appears to create specific vulnerabilities, particularly to bacterial pathogens, while its effect on subsequent acute viral respiratory infections is more nuanced and an area of active investigation.
6.1 The Increased Risk and Mortality of Bacterial Co-infections

One of the clearest and most dangerous interactions is the synergy between SARS-CoV-2 and bacterial pathogens. Secondary bacterial pneumonia and bacteremia (bacterial infections of the bloodstream) have emerged as a major, and often underappreciated, driver of morbidity and mortality in patients hospitalized with COVID-19.52 The lung damage and systemic immune disruption caused by the virus create an environment ripe for bacterial invasion.

While clinically relevant bacterial co-infections are identified in a minority of hospitalized COVID-19 patients—around 6.0% in one large surveillance network—their impact on outcomes is disproportionately severe.54 After adjusting for other risk factors, hospitalized COVID-19 patients with a bacterial co-infection have a more than two-fold higher risk of in-hospital death compared to those without a co-infection (relative risk of 2.28).54 The risk of other severe outcomes is similarly elevated, with a roughly two-fold increased need for intensive care unit (ICU) admission and a three-fold increased need for mechanical ventilation.54 The most commonly implicated bacterial pathogens include Staphylococcus aureus and various gram-negative rods such as Pseudomonas aeruginosa and Klebsiella pneumoniae.54 These findings demonstrate a clear and deadly interaction where SARS-CoV-2 infection significantly worsens the prognosis of a subsequent bacterial infection, contributing substantially to the overall mortality of the disease.
6.2 A Nuanced View on Subsequent Respiratory Virus Susceptibility (Influenza and RSV)

The hypothesis that the immune dysregulation caused by COVID-19 would lead to a broad increase in susceptibility to all other respiratory viruses, such as influenza and Respiratory Syncytial Virus (RSV), is mechanistically plausible but not consistently supported by the current epidemiological data. Some theories have proposed that COVID-induced immune dysfunction could be a contributing factor to the unusual and intense surges of RSV seen in the post-pandemic era.37 However, disentangling this potential biological effect from the profound impact of the "immunity gap"—the widespread, temporary loss of population-level immunity to common viruses due to years of non-pharmaceutical interventions like masking and social distancing—is extremely challenging.58

Indeed, a large retrospective cohort study of children under five years old yielded surprising results that directly challenge the simple immune suppression hypothesis. This study found that the odds of a subsequent RSV infection or any other respiratory tract infection within a 180-day period were actually lower in the group of children who had a prior SARS-CoV-2 infection compared to a control group that had a prior influenza infection.60 This finding suggests a more complex interaction than simple immunosuppression. It is possible that the innate immune activation triggered by SARS-CoV-2 could create a temporary state of heightened, non-specific antiviral defense that interferes with the replication of other respiratory viruses for a period of months. This highlights that the immune dysregulation caused by SARS-CoV-2 is not a monolith; it may create specific vulnerabilities (e.g., to bacteria and latent viruses) while having different, or even temporarily protective, effects against other classes of pathogens.

Regardless of the precise nature of the interaction, when these viruses do co-circulate, SARS-CoV-2 has consistently been associated with more severe outcomes. Throughout the pandemic, COVID-19 has been linked to a higher risk of hospitalization and long-term mortality compared to seasonal influenza or RSV, although this gap in severity has narrowed over time with the evolution of less virulent viral variants and the build-up of population immunity through vaccination and prior infection.62
Synthesis and Concluding Analysis

The body of evidence synthesized in this report strongly supports the overarching hypothesis that the ongoing global circulation of SARS-CoV-2 is contributing to a sicker world population. This conclusion is not based on a single mechanism but on two primary, interconnected pathways of disease burden: the direct induction of a widespread chronic illness (PASC) and the indirect effect of altering host immunity, which in turn modifies interactions with other pathogens.

The first pathway, infection-induced chronic disease, is now firmly established. Post-Acute Sequelae of COVID-19 is a common outcome, affecting an estimated 36% of infected individuals with a diverse and debilitating array of multi-system symptoms that persist for years in a significant minority.7 This is not a prolonged recovery but a distinct chronic condition driven by a vicious cycle of persistent immune dysregulation, potential viral reservoirs, microvascular clotting and hypoxia, and the triggering of autoimmune processes. The fact that the cumulative risk of long-term sequelae appears to increase with each reinfection underscores the grave public health threat posed by the continued, widespread transmission of the virus.31 The result is a mass disabling event that has created a massive new global population of chronically ill individuals, placing an unprecedented and lasting strain on healthcare systems, economies, and social support structures.

The second pathway, pathogen-pathogen interaction, stems from the same root cause: the profound and persistent disruption of the human immune system by SARS-CoV-2. This immune dysregulation is not a simple, uniform suppression but a complex recalibration of the immune system toward a dysfunctional, pro-inflammatory, and exhausted state. This state has clear and demonstrable consequences for the host's ability to manage other infectious threats. The evidence for this is strongest in the realms of latent virus reactivation and bacterial co-infection. The compromised T-cell function following COVID-19 directly leads to an increased incidence of diseases like shingles (VZV reactivation) and is strongly implicated as a driver of Long COVID symptoms through the reactivation of EBV.44 Similarly, the data unequivocally show that bacterial co-infections in hospitalized COVID-19 patients are associated with a catastrophic increase in mortality and morbidity.54

The interaction with other acute respiratory viruses, such as influenza and RSV, is more nuanced. The evidence does not currently support a simple model of increased susceptibility; in fact, some data suggest a possible temporary protective effect, complicating the narrative.60 This highlights the complexity of the post-COVID immune landscape and the need to differentiate between different types of pathogenic threats. Nonetheless, the clear and severe consequences of post-COVID bacterial and latent viral diseases are sufficient to validate the second part of the hypothesis.

Table 2: Summary of Evidence for Pathogen-Pathogen Interactions Post-SARS-CoV-2 Infection

In conclusion, these two pathways are not separate phenomena but are two facets of the same core problem. The immune dysregulation that drives the internal symptoms of Long COVID is the same immune dysregulation that leaves the host vulnerable to external and internal pathogenic threats. Therefore, the statement that "Ongoing global population infection with SARS-CoV-2 will make the world sicker, through both infection-induced chronic disease and pathogen-pathogen interaction" is a well-supported and accurate assessment of the enduring legacy of the COVID-19 pandemic.
Recommendations for Public Health, Clinical Practice, and Future Research

Based on the comprehensive analysis of the evidence, the following recommendations are proposed to mitigate the long-term health consequences of SARS-CoV-2 infection:
Public Health

    Shift in Paradigm: Public health narratives must shift from focusing solely on acute hospitalization and death to acknowledging Long COVID as a common, chronic, and disabling outcome of SARS-CoV-2 infection. The concept of a "mild" infection must be re-evaluated in light of the significant risk of long-term sequelae.

    Prioritize Transmission Reduction: Given that the risk of Long COVID is cumulative with each infection, public health strategies should prioritize the reduction of community transmission. This includes promoting and investing in universal measures such as improved indoor air quality through ventilation and high-efficiency filtration, which reduce the risk for all airborne pathogens.

    Public Awareness and Support Systems: Launch public awareness campaigns about the risks and realities of Long COVID, ME/CFS, and other post-infectious illnesses. Establish and fund robust social and financial support systems for individuals disabled by these conditions.

Clinical Practice

    Increased Clinical Suspicion: Clinicians should maintain a high index of suspicion for Long COVID-related conditions in patients with a history of SARS-CoV-2 infection. This includes screening for new-onset autoimmune diseases, Mast Cell Activation Syndrome, and autonomic dysfunction (e.g., POTS).

    Proactive Management of Co-infections: In hospitalized COVID-19 patients, there should be aggressive surveillance for and treatment of secondary bacterial infections, as these are a key driver of mortality.

    Interdisciplinary Care Models: The multi-system nature of Long COVID necessitates the development of integrated, interdisciplinary care clinics that can address the complex needs of patients, drawing on expertise from cardiology, pulmonology, neurology, immunology, and rehabilitation medicine.

    Validation and Empathy: Given the often-invisible nature of the illness and the potential for normal routine test results, it is imperative for healthcare providers to validate patient-reported symptoms and approach care with empathy, recognizing the well-documented biological underpinnings of the disease.1

Future Research

    Longitudinal Cohort Studies: There is an urgent need for large-scale, long-term longitudinal cohort studies that comprehensively track the immune landscape and clinical outcomes in individuals following SARS-CoV-2 infection, including multiple reinfections. These studies are essential for understanding the full trajectory of post-COVID immune dysregulation.

    Mechanistic Clinical Trials: Research must move beyond observational studies to randomized controlled trials targeting the core pathophysiological mechanisms identified in this report. Priority areas include trials of antivirals to clear persistent viral reservoirs, immunomodulatory agents to quell chronic inflammation, and anti-thrombotic or fibrinolytic therapies to address microclotting.

    Biomarker Discovery: A concerted effort is needed to identify reliable biomarkers for diagnosing Long COVID and stratifying patients based on their underlying pathophysiology (e.g., viral persistence vs. autoimmunity vs. microclots). This is a critical step toward developing personalized medicine approaches for this heterogeneous condition.

Acknowledgement

I acknowledge the assistance of Gemini AI in the preparation of the subject research plan, the execution of the research, and the preparation of this report.
Works cited

    Long COVID Basics - CDC, accessed August 15, 2025, https://www.cdc.gov/long-covid/about/index.html

    Postacute Sequelae of COVID (PASC or Long COVID): An Evidenced-Based Approach - PMC - National Institutes of Health (NIH) |, accessed August 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11363684/

    A systematic review and meta-analysis of long COVID symptoms - PMC - PubMed Central, accessed August 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10220332/

    (PDF) Global prevalence of long COVID and its most common symptoms among healthcare workers: a systematic review and meta-analysis - ResearchGate, accessed August 15, 2025, https://www.researchgate.net/publication/390920487_Global_prevalence_of_long_COVID_and_its_most_common_symptoms_among_healthcare_workers_a_systematic_review_and_meta-analysis

    Long COVID Signs and Symptoms - CDC, accessed August 15, 2025, https://www.cdc.gov/long-covid/signs-symptoms/index.html

    Neurological sequelae of long COVID: a comprehensive review of diagnostic imaging, underlying mechanisms, and potential therapeutics - Frontiers, accessed August 15, 2025, https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1465787/full

    (PDF) Global Prevalence of Long COVID, its Subtypes and Risk ..., accessed August 15, 2025, https://www.researchgate.net/publication/387852530_Global_Prevalence_of_Long_COVID_its_Subtypes_and_Risk_factors_An_Updated_Systematic_Review_and_Meta-Analysis

    Immunomodulatory Mechanisms Underlying Neurological Manifestations in Long COVID: Implications for Immune-Mediated Neurodegeneration - MDPI, accessed August 15, 2025, https://www.mdpi.com/1422-0067/26/13/6214

    Heart Problems After Covid-19 - Cleveland Clinic, accessed August 15, 2025, https://my.clevelandclinic.org/health/articles/heart-problems-after-covid

    Long-COVID Syndrome and the Cardiovascular System: A Review of Neurocardiologic Effects on Multiple Systems - PubMed Central, accessed August 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9524329/

    COVID-19: long-term respiratory consequences - PMC, accessed August 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9632533/

    Recovery and symptom trajectories up to two years after SARS-CoV-2 infection: population based, longitudinal cohort study | The BMJ, accessed August 15, 2025, https://www.bmj.com/content/381/bmj-2022-074425

    Persistence of Long COVID Symptoms Two Years After SARS-CoV-2 Infection: A Prospective Longitudinal Cohort Study - MDPI, accessed August 15, 2025, https://www.mdpi.com/1999-4915/16/12/1955

    Persistence of Long COVID Symptoms Two Years After SARS-CoV-2 Infection: A Prospective Longitudinal Cohort Study - ResearchGate, accessed August 15, 2025, https://www.researchgate.net/publication/387269769_Persistence_of_Long_COVID_Symptoms_Two_Years_After_SARS-CoV-2_Infection_A_Prospective_Longitudinal_Cohort_Study

    Financial impact of long COVID can linger for years, study finds - CIDRAP, accessed August 15, 2025, https://www.cidrap.umn.edu/covid-19/financial-impact-long-covid-can-linger-years-study-finds

    How does post COVID differ from other post-viral conditions in ..., accessed August 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10850405/

    A review of cytokine-based pathophysiology of Long ... - Frontiers, accessed August 15, 2025, https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2023.1011936/full

    Persistent immune dysregulation and metabolic alterations following SARS-CoV-2 infection - PMC - PubMed Central, accessed August 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12047922/

    In Patients with Long COVID, Immune Cells Don't Follow the Rules - Gladstone Institutes, accessed August 15, 2025, https://gladstone.org/news/patients-long-covid-immune-cells-dont-follow-rules

    Severe COVID-19 may lead to long-term innate immune system changes, accessed August 15, 2025, https://www.nih.gov/news-events/news-releases/severe-covid-19-may-lead-long-term-innate-immune-system-changes

    Severe COVID-19 Can Alter Long-term Immune System Response | Newsroom, accessed August 15, 2025, https://news.weill.cornell.edu/news/2023/08/severe-covid-19-can-alter-long-term-immune-system-response

    Long COVID: The Theory of Viral Persistence - RTHM, accessed August 15, 2025, https://rthm.com/articles/long-covid-the-theory-of-viral-persistence/

    Long COVID: pathophysiological factors and abnormalities of ..., accessed August 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10113134/

    Proteomics of fibrin amyloid microclots in long COVID/post-acute sequelae of COVID- 19 (PASC) - DTU Research Database, accessed August 15, 2025, https://orbit.dtu.dk/files/298168152/s12933_022_01623_4.pdf

    Can COVID Trigger Autoimmune Diseases? Risk Explained - GoodRx, accessed August 15, 2025, https://www.goodrx.com/health-topic/autoimmune/can-covid-19-cause-autoimmune-diseases

    Long COVID: What People with Autoimmune Disease and Chronic Illness Need to Know, accessed August 15, 2025, https://www.autoimmuneinstitute.org/long-covid-faq/

    Immunological dysfunction and mast cell activation syndrome in ..., accessed August 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10166245/

    Risk of New-Onset Long COVID Following Reinfection With Severe Acute Respiratory Syndrome Coronavirus 2: A Community-Based Cohort Study - Oxford Academic, accessed August 15, 2025, https://academic.oup.com/ofid/article/10/11/ofad493/7289449

    Data suggest COVID-19 reinfections less likely to cause long COVID, accessed August 15, 2025, https://www.cidrap.umn.edu/covid-19/data-suggest-covid-19-reinfections-less-likely-cause-long-covid

    www.cidrap.umn.edu, accessed August 15, 2025, https://www.cidrap.umn.edu/covid-19/data-suggest-covid-19-reinfections-less-likely-cause-long-covid#:~:text=Risk%2015%25%20after%20first%20infection%2C%206%25%20after%20second&text=With%20both%20surveys%20combined%2C%20the,cases%20than%20by%20COVID%20controls.

    SARS-CoV-2 Reinfections and Long COVID in the Post-Omicron ..., accessed August 15, 2025, https://www.mdpi.com/1422-0067/24/16/12962

    Every COVID Infection Increases Your Risk of Long COVID, Study Warns - UNMC, accessed August 15, 2025, https://www.unmc.edu/healthsecurity/transmission/2023/12/27/every-covid-infection-increases-your-risk-of-long-covid-study-warns/

    Multiple Covid Infections Associated with Long Covid - SBU News - Stony Brook University, accessed August 15, 2025, https://news.stonybrook.edu/newsroom/press-release/medical/multiple-covid-infections-associated-with-long-covid/

    Study: Multiple Covid Infections Associated with Long Covid - SBU News, accessed August 15, 2025, https://news.stonybrook.edu/university/study-multiple-covid-infections-associated-with-long-covid/

    Lasting impact of long COVID and the protective benefits of vaccination - News-Medical, accessed August 15, 2025, https://www.news-medical.net/news/20250219/Lasting-impact-of-long-COVID-and-the-protective-benefits-of-vaccination.aspx

    The Impact of COVID Vaccination on Symptoms of Long COVID: An International Survey of People with Lived Experience of Long COVID, accessed August 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9146071/

    COVID-19 and Immune Dysregulation, a Summary and Resource ..., accessed August 15, 2025, https://whn.global/covid-19-and-immune-dysregulation-a-summary-and-resource/

    COVID-19 leads to long-term changes in the immune system, study shows, accessed August 15, 2025, https://www.immunizecolorado.org/covid-19-leads-to-long-term-changes-in-the-immune-system-study-shows/

    Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past, accessed August 15, 2025, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.01949/full

    SYNTHESIS - Evidence for Long-term Impacts of COVID-19 on ..., accessed August 15, 2025, https://www.publichealthontario.ca/-/media/Documents/nCoV/COVID-WWKSF/2023/08/long-term-impacts-covid-19-immune-cells-autoimmune-adults.pdf?rev=ee9ec7f21c6e45898a31ca8c9517d089&sc_lang=en

    SARS-CoV-2-Induced Immunosuppression: A Molecular Mimicry Syndrome - PMC, accessed August 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9282940/

    Autoimmunity and Immunodeficiency in Severe SARS-CoV-2 Infection and Prolonged COVID-19 - PubMed Central, accessed August 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9857622/

    SARS-CoV-2 and HIV-1: So Different yet so Alike. Immune Response at the Cellular and Molecular Level, accessed August 15, 2025, https://www.medsci.org/v19p1787.htm

    Viral Reactivation and Long COVID - RTHM, accessed August 15, 2025, https://rthm.com/articles/viral-reactivation-and-long-covid/

    If you've recently had Covid, look out for shingles - The University of Auckland, accessed August 15, 2025, https://www.auckland.ac.nz/en/news/2022/08/16/If-youve-had-Covid-look-out-for-shingles.html

    Exploring common pathogenic association between Epstein Barr virus infection and long-COVID by integrating RNA-Seq and molecular dynamics simulations - Frontiers, accessed August 15, 2025, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1435170/full

    COVID-19 and primary immunodeficiency - Immune Deficiency Foundation, accessed August 15, 2025, https://primaryimmune.org/living-primary-immunodeficiency/general-care/pi-and-covid

    SARS-COV-2 infections in inborn errors of immunity: A single center study - Frontiers, accessed August 15, 2025, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.1035571/full

    COVID-19 and People with HIV - HIV.gov, accessed August 15, 2025, https://www.hiv.gov/hiv-basics/staying-in-hiv-care/other-related-health-issues/coronavirus-covid-19

    Opportunistic Infections - HIV.gov, accessed August 15, 2025, https://www.hiv.gov/hiv-basics/staying-in-hiv-care/other-related-health-issues/opportunistic-infections

    COVID-19-associated opportunistic infections: a snapshot on the current reports - PubMed, accessed August 15, 2025, https://pubmed.ncbi.nlm.nih.gov/34424451/

    Secondary Bacterial Pneumonia Drove Many COVID-19 Deaths - News Center, accessed August 15, 2025, https://news.feinberg.northwestern.edu/2023/05/05/secondary-bacterial-pneumonia-drove-many-covid-19-deaths/

    Bacterial Superinfections After SARS-CoV-2 Pneumonia: Antimicrobial Resistance Patterns, Impact on Inflammatory Profiles, Severity Scores, and Clinical Outcomes - PMC, accessed August 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12109590/

    Bacterial co-infections linked to higher risk of death in US COVID ..., accessed August 15, 2025, https://www.cidrap.umn.edu/antimicrobial-stewardship/bacterial-co-infections-linked-higher-risk-death-us-covid-patients

    COVID-19: Bacterial co-infection is a major risk factor for death, ICU admission and mechanical ventilation - University of Alabama at Birmingham, accessed August 15, 2025, https://www.uab.edu/news/research-innovation/covid-19-bacterial-co-infection-is-a-major-risk-factor-for-death-icu-admission-and-mechanical-ventilation

    Bacterial co-infections cause twofold increase in mortality in COVID patients: study, accessed August 15, 2025, https://www.unmc.edu/healthsecurity/transmission/2023/03/07/bacterial-co-infections-cause-twofold-increase-in-mortality-in-covid-patients-study/

    Secondary Bacterial Pneumonias and Bloodstream Infections in Patients Hospitalized with COVID-19 | Annals of the American Thoracic Society - ATS Journals, accessed August 15, 2025, https://www.atsjournals.org/doi/full/10.1513/AnnalsATS.202009-1093RL

    Upsurge of acute respiratory infections among children post-COVID-19 pandemic, accessed August 15, 2025, https://www.the-innovation.org/article/doi/10.59717/j.xinn-med.2024.100070

    Why has the epidemiology of RSV changed during the COVID-19 pandemic? - PMC, accessed August 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10359735/

    Respiratory and Other Infections Following COVID | Pediatrics - AAP Publications, accessed August 15, 2025, https://publications.aap.org/pediatrics/article/doi/10.1542/peds.2024-068280/203031/Respiratory-and-Other-Infections-Following-COVID

    Respiratory and other infections following COVID, accessed August 15, 2025, https://recovercovid.org/publications/respiratory-and-other-infections-following-covid

    COVID-19 vs. flu: Similarities and differences - Mayo Clinic, accessed August 15, 2025, https://www.mayoclinic.org/diseases-conditions/coronavirus/in-depth/coronavirus-vs-flu/art-20490339

    COVID-19 Associated With More Severe Outcomes Than Flu or RSV - U.S. Pharmacist, accessed August 15, 2025, https://www.uspharmacist.com/article/covid19-associated-with-more-severe-outcomes-than-flu-or-rsv

    Study Shows Hospital Outcomes for Flu and COVID-19 Have Become More Similar - CDC, accessed August 15, 2025, https://www.cdc.gov/flu/whats-new/2023-2024-hospital-outcomes.html

Subscribe to David Lingenfelter, PhD
Launched 7 months ago
By subscribing, I agree to Substack's Terms of Use, and acknowledge its Information Collection Notice and Privacy Policy.
3 Likes
∙
1 Restack
Discussion about this post
The Vascular Pathophysiology of SARS-CoV-2: Mechanisms, Manifestations, and Long-Term Sequelae
Emerging consensus shows that SARS-CoV-2 primarily disrupts the vascular system, despite initial respiratory symptoms.
Jul 29 • David Lingenfelter, PhD
8
The Gut-Centric Pathogenesis of Long COVID: A Synthesis of Mechanistic and Clinical Evidence Linking SARS-CoV-2, Microbiome Dysbiosis, and...
Persistent SARS-CoV-2 infection in the gut drives microbiome dysbiosis, barrier failure, and systemic inflammation, forming a core mechanism of Long...
Jul 31 • David Lingenfelter, PhD
7
An Expert Report on Metformin for the Prevention and Treatment of Long COVID
Metformin, when taken early during COVID-19 infection, significantly reduces the risk of developing Long COVID, with emerging trials exploring its...
Aug 1 • David Lingenfelter, PhD
4

Ready for more?
© 2025 David Lingenfelter
----------------------------------
[*/quote*]